{
    "id": 370,
    "fullName": "BRAF mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRAF mutant indicates an unspecified mutation in the BRAF gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "mutant",
    "createDate": "03/13/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11203,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1916,
                "therapyName": "Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16511,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10039,
                    "pubMedId": null,
                    "title": "Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1823,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 834,
                "therapyName": "Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2158,
                    "pubMedId": 22460902,
                    "title": "Systematic identification of genomic markers of drug sensitivity in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22460902"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11693,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12133,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-na\u00efve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10108,
                    "pubMedId": 28611198,
                    "title": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611198"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11978,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9943,
                    "pubMedId": null,
                    "title": "Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK- 580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6738,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11695,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7827,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12194,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8465,
                    "pubMedId": 28152546,
                    "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4764,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3635,
                "therapyName": "Tubastatin A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4713,
                    "pubMedId": 25957812,
                    "title": "Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25957812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9612,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 28947956).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12147,
                    "pubMedId": 28947956,
                    "title": "Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28947956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7228,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14051,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines harboring BRAF mutations demonstrated increased sensitivity to RAF709 compared to BRAF wild-type cells in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 713,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11223,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5911,
                "therapyName": "PET-16 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8968,
                    "pubMedId": 26984758,
                    "title": "HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26984758"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19112,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BRAF mutations aid in the diagnosis of splenic marginal zone lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50750,
                "name": "splenic marginal zone lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3911,
                "therapyName": "E6201 + LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11066,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2874,
                "therapyName": "CC-90003",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9060,
                    "pubMedId": null,
                    "title": "A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186986.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10124,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13934,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6302,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1028,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 744,
                    "pubMedId": 23406027,
                    "title": "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23406027"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11932,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1992,
                "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9918,
                    "pubMedId": 27770002,
                    "title": "Triple Therapy Improves Colorectal Cancer Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27770002"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17210,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in a patients with BRAF-mutant melanoma in a dose escalation study, and partial response in 33% (2/6) of BRAF-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15236,
                    "pubMedId": null,
                    "title": "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_248211.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10259,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9039,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4864,
                "therapyName": "S63845 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8542,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 195,
                    "pubMedId": 24422853,
                    "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12701,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring a BRAF mutation (PMID: 29247021).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6961,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5987,
                    "pubMedId": null,
                    "title": "Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).",
                    "url": "http://meetinglibrary.asco.org/content/166237-176"
                },
                {
                    "id": 9149,
                    "pubMedId": 28363909,
                    "title": "A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363909"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10057,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-na\u00efve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1238,
                "therapyName": "Vemurafenib + Voruciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5185,
                    "pubMedId": null,
                    "title": "Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.",
                    "url": "http://meetinglibrary.asco.org/content/153239-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17310,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LXH 254 treatment resulted in partial response in 2.6% (2/75) and stable disease in 33% (25/75) of patients with advanced solid tumors harboring MAPK pathway alterations, one of the patient achieved partial response harbored a BRAF mutation (J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586; NCT02607813).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4442,
                "therapyName": "LXH 254",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15361,
                    "pubMedId": null,
                    "title": "A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2586"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6731,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20577,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LY3009120 did not achieve expected pharmacodynamic effects, resulted in stable disease as best overall response in 5 of 12 patients with advanced or metastatic cancer harboring BRAF mutations (PMID: 31645440; NCT02014116).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17943,
                    "pubMedId": 31645440,
                    "title": "A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31645440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12282,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 treatment resulted in tumor regression in BRAF mutant-melanoma cell line xenograft models (PMID: 28775144).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15662,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6697,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7320,
                    "pubMedId": null,
                    "title": "105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors",
                    "url": "http://www.ejcancersupplements.com/article/S1359-6349%2810%2971810-3/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 2893,
                "name": "cervix carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1337,
                "therapyName": "Buparlisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11699,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12191,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14940,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant colorectal cancer cell lines in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10120,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6687,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11697,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 701,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 467,
                    "pubMedId": 22608338,
                    "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22608338"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10965,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8965,
                    "pubMedId": null,
                    "title": "KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics",
                    "url": "http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4865,
                "therapyName": "S63845 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21302,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of UNC2025 and Zelboraf (vemurafenib) resulted in greater inhibition of colony formation and apoptotic induction in melanoma cells harboring a BRAF mutation in culture and led to a higher degree of tumor growth inhibition in a patient derived xenograft (PDX) model of melanoma with a BRAF mutation when compared to either therapy alone (PMID: 30482852).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 9743,
                "therapyName": "UNC2025 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18602,
                    "pubMedId": 30482852,
                    "title": "Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30482852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11701,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12099,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10039,
                    "pubMedId": null,
                    "title": "Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10254,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 5317,
                "therapyName": "CGM097 + Dabrafenib + Navitoclax + PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17731,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 8599,
                "therapyName": "Pimasertib + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15755,
                    "pubMedId": 30585255,
                    "title": "A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30585255"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8097,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 2285,
                "therapyName": "CGM097 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7241,
                    "pubMedId": null,
                    "title": "Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/5466"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) prevented cell growth and inhibited MTORC1 and MTORC2 signaling in rapamycin-resistant breast cancer cells harboring mutations in BRAF, CDKN2A, KRAS,NF2 and TP53 (PMID: 25261369).",
            "molecularProfile": {
                "id": 5003,
                "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2135,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).",
            "molecularProfile": {
                "id": 5415,
                "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3688,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3796,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15931,
                "profileName": "BRAF mut NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 3518,
                "therapyName": "GSK2636771 + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1225,
                "therapyName": "SAR260301 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1052,
                "therapyName": "SAR260301",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7774,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 4573,
                "therapyName": "SAR260301 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4456,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5628,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5629,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6100,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4056,
                "therapyName": "Encorafenib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6111,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4042,
                "therapyName": "Alpelisib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6127,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4059,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4061,
                "therapyName": "AZD6482 + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6137,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4068,
                "therapyName": "Encorafenib + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4069,
                "therapyName": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4046,
                "therapyName": "NVP-AEW541 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4060,
                "therapyName": "AZD6482 + Binimetinib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4062,
                "therapyName": "Alpelisib + AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4063,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4064,
                "therapyName": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4049,
                "therapyName": "Alpelisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4047,
                "therapyName": "Alpelisib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4065,
                "therapyName": "Alpelisib + Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6136,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4067,
                "therapyName": "GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6101,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 3714,
                "therapyName": "Alpelisib + AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4053,
                "therapyName": "Binimetinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6690,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23670,
                "profileName": "BRAF mut CDKN2A mut KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7796,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7795,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing both Stag2 and Stag3 expression levels through shRNA knockdown in BRAF mutated melanoma cells resulted in further decreased response to Zelboraf (vemurafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26044,
                "profileName": "BRAF mut STAG2 dec exp STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26062,
                "profileName": "BRAF mut KRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to PDGFRB over expression in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26063,
                "profileName": "BRAF mut PDGFRB over exp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to CCND1 amplification in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26064,
                "profileName": "BRAF mut CCND1 amp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to MAP3K8 amplification in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26066,
                "profileName": "BRAF mut MAP3K8 amp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of ISIS-STAT3rx (AZD9150) and Selumetinib (AZD6244) resulted in inhibition of Stat3 signaling and enhanced apoptosis in BRAF-mutant colorectal cancer cells (PMID: 25813020).",
            "molecularProfile": {
                "id": 26310,
                "profileName": "BRAF mut STAT3 pos"
            },
            "therapy": {
                "id": 4718,
                "therapyName": "AZD9150 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6639,
                    "pubMedId": 25813020,
                    "title": "HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25813020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8539,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Met expression via shRNA sensitized colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26399,
                "profileName": "BRAF mut MET dec exp NF1 inact mut"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Raf1 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26400,
                "profileName": "BRAF mut RAF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Shoc2 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26401,
                "profileName": "BRAF mut SHOC2 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26402,
                "profileName": "BRAF mut PTPN11 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4788,
                "therapyName": "PLX4720 + SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC-87877 and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4790,
                "therapyName": "NSC-87877 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and RAF265 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4793,
                "therapyName": "RAF265 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 and VTX-11e combination treatment inhibited proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture, but did not exhibit synergy (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4796,
                "therapyName": "AZ628 + VTX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) and Selumetinib (AZD6244) demonstrated modest synergy inhibiting Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4797,
                "therapyName": "Dabrafenib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and RAF265 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4793,
                "therapyName": "RAF265 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) and Mekinist (trametinib) demonstrated modest synergy inhibiting Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4787,
                "therapyName": "Crizotinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) and PLX4720 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4789,
                "therapyName": "Foretinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MLN2480 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4794,
                "therapyName": "MLN2480 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation, induced apoptosis in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MLN2480 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4794,
                "therapyName": "MLN2480 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26406,
                "profileName": "BRAF mut KRAS G12V"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant melanoma cells with decreased Nf1 expression level via shRNA knock-down were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26407,
                "profileName": "BRAF mut NF1 dec exp"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over-expressing MAP2K1 Q56P in colorectal cancer cells harboring both BRAF mutation and NF1 inactivating mutation resulted in resistance to AZ628 and Selumetinib (AZD6244) combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26411,
                "profileName": "BRAF mut MAP2K1 Q56P NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9443,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and expressing DTL, and resistant to BRAF inhibitors, demonstrated sensitivity to MLN4924 in xenograft models, resulting in some inhibition of tumor growth (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MLN4924 and PLX4720 resulted in a synergistic effect in a melanoma cell line xenograft model resistant to BRAF inhibitors, and harboring a BRAF mutation and DTL expression (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 5017,
                "therapyName": "MLN4924 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9934,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 27213,
                "profileName": "BRAF mut TP53 mut"
            },
            "therapy": {
                "id": 5318,
                "therapyName": "Alpelisib + Dabrafenib + Erlotinib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Altiratinib (DCC-2701) to Mekinist (trametinib) therapy resulted in decreased proliferation of a BRAF-mutant melanoma cell line with HGF-mediated resistance to Mekinist (trametinib) in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 27235,
                "profileName": "BRAF mut HGF pos"
            },
            "therapy": {
                "id": 5362,
                "therapyName": "Altiratinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10776,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",
            "molecularProfile": {
                "id": 27794,
                "profileName": "BRAF mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line co-expressing RAF1 and a BRAF mutation demonstrated inhibition of downstream Mapk1 signaling when treated with AZ628 (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
            "molecularProfile": {
                "id": 27912,
                "profileName": "BRAF mut RAF1 pos"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9096,
                    "pubMedId": null,
                    "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                    "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16069,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).",
            "molecularProfile": {
                "id": 31466,
                "profileName": "BRAF mut IDH1 wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14204,
                    "pubMedId": 30742119,
                    "title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30742119"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 465,
            "profileName": "BRAF mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2336,
            "profileName": "BRAF mut PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3307,
            "profileName": "BRAF mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5003,
            "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5415,
            "profileName": "APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14782,
            "profileName": "BRAF mut NRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 15931,
            "profileName": "BRAF mut NRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18163,
            "profileName": "BRAF mut PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21306,
            "profileName": "BRAF mut PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21308,
            "profileName": "BRAF mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22705,
            "profileName": "BRAF mut PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23670,
            "profileName": "BRAF mut CDKN2A mut KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26042,
            "profileName": "BRAF mut STAG2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26043,
            "profileName": "BRAF mut STAG3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26044,
            "profileName": "BRAF mut STAG2 dec exp STAG3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26062,
            "profileName": "BRAF mut KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26063,
            "profileName": "BRAF mut PDGFRB over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26064,
            "profileName": "BRAF mut CCND1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26066,
            "profileName": "BRAF mut MAP3K8 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26310,
            "profileName": "BRAF mut STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26352,
            "profileName": "BRAF mut RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26399,
            "profileName": "BRAF mut MET dec exp NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26400,
            "profileName": "BRAF mut RAF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26401,
            "profileName": "BRAF mut SHOC2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26402,
            "profileName": "BRAF mut PTPN11 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26403,
            "profileName": "BRAF mut NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26406,
            "profileName": "BRAF mut KRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26407,
            "profileName": "BRAF mut NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26411,
            "profileName": "BRAF mut MAP2K1 Q56P NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26850,
            "profileName": "BRAF mut DTL pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27213,
            "profileName": "BRAF mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27235,
            "profileName": "BRAF mut HGF pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27794,
            "profileName": "BRAF mut PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27912,
            "profileName": "BRAF mut RAF1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31466,
            "profileName": "BRAF mut IDH1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}